The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has announced the first cohort of drug discovery projects to receive its Collaborative Discovery Programme (CDP) funding. The £3 ($3.9) million programme, funded by LifeArc, will support six early-stage novel antimicrobial projects over two years to accelerate new treatments for lung infections in people with CF. The […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!